130 related articles for article (PubMed ID: 16906281)
1. Urinary NO3 excretion and renal failure in indinavir-treated patients.
Eira M; Araujo M; Seguro AC
Braz J Med Biol Res; 2006 Aug; 39(8):1065-70. PubMed ID: 16906281
[TBL] [Abstract][Full Text] [Related]
2. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.
van Rossum AM; Dieleman JP; Fraaij PL; Cransberg K; Hartwig NG; Burger DM; Gyssens IC; de Groot R
Pediatrics; 2002 Aug; 110(2 Pt 1):e19. PubMed ID: 12165618
[TBL] [Abstract][Full Text] [Related]
3. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P
HIV Med; 2005 Nov; 6(6):410-20. PubMed ID: 16268823
[TBL] [Abstract][Full Text] [Related]
4. Vasodilator agents protect against indinavir nephrotoxicity.
de Araujo M; Seguro AC
Antivir Ther; 2003 Aug; 8(4):295-9. PubMed ID: 14518698
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
[TBL] [Abstract][Full Text] [Related]
6. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
[TBL] [Abstract][Full Text] [Related]
7. Changes in renal function associated with indinavir.
Boubaker K; Sudre P; Bally F; Vogel G; Meuwly JY; Glauser MP; Telenti A
AIDS; 1998 Dec; 12(18):F249-54. PubMed ID: 9875572
[TBL] [Abstract][Full Text] [Related]
8. Anti-HIV agents. Efavirenz versus indinavir: who really wins?
TreatmentUpdate; 2000 Feb; 12(1):4-5. PubMed ID: 12125628
[No Abstract] [Full Text] [Related]
9. Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
Danel C; Moh R; Peytavin G; Anzian A; Minga A; Gomis OB; Seri B; Nzunettu G; Gabillard D; Salamon R; Bissagnene E; Anglaret X
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):62-6. PubMed ID: 17263634
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of indinavir-associated renal complications in Thai HIV-infected patients.
Avihingsanon A; Avihingsanon Y; Darnpornprasert P; Kerr S; Ungsedhapand C; Duncombe C; Ubolyam S; Ruxrungtham K; Phanuphak P
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S21-7. PubMed ID: 17044450
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
12. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
Cressey TR; Urien S; Hirt D; Halue G; Techapornroong M; Bowonwatanuwong C; Leenasirimakul P; Treluyer JM; Jourdain G; Lallemant M;
Ther Drug Monit; 2011 Feb; 33(1):25-31. PubMed ID: 21233689
[TBL] [Abstract][Full Text] [Related]
13. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
[TBL] [Abstract][Full Text] [Related]
14. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir.
Dieleman JP; van Rossum AM; Stricker BC; Sturkenboom MC; de Groot R; Telgt D; Blok WL; Burger DM; Blijenberg BG; Zietse R; Gyssens IC
J Acquir Immune Defic Syndr; 2003 Feb; 32(2):135-42. PubMed ID: 12571522
[TBL] [Abstract][Full Text] [Related]
15. [Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)].
Tanon AK; Eholié SP; Polneau S; Kra O; Ello F; Ehui E; Aoussi E; Djadji A; Kakou A; Bissagnéné E; Kadio A
Med Mal Infect; 2008 May; 38(5):264-9. PubMed ID: 18395375
[TBL] [Abstract][Full Text] [Related]
16. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
[TBL] [Abstract][Full Text] [Related]
17. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JM; Phanuphak P; Cooper DA; Burger DM
J Antimicrob Chemother; 2006 Jun; 57(6):1161-7. PubMed ID: 16595641
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz in HIV infection.
Casado JL; Moreno S
N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
[No Abstract] [Full Text] [Related]
19. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
Autar RS; Boyd MA; Wit FW; Ruxrungthams K; Sankote J; Lange J; Cooper DA; Phanuphak P; Burger DM; Reiss P
Antivir Ther; 2007; 12(8):1265-71. PubMed ID: 18240866
[TBL] [Abstract][Full Text] [Related]
20. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
